DOXAZOSIN

Doxazosin Adverse Events Reported to the FDA Over Time

How are Doxazosin adverse event reports trending over time?

This graph shows volume of adverse events submitted to the FDA by quarter for Doxazosin, as well as related generic and/or brandname drugs containing the same primary active ingredients. Adverse events are counted if Doxazosin is flagged as the suspect drug causing the adverse event.

Most Common Doxazosin Adverse Events Reported to the FDA

What are the most common Doxazosin adverse events reported to the FDA?

Hypotension	254 (2.46%)
Dizziness	203 (1.97%)
Drug Interaction	184 (1.78%)
Loss Of Consciousness	139 (1.35%)
Drug Ineffective	138 (1.34%)
Syncope	132 (1.28%)
Hypertension	126 (1.22%)
Dyspnoea	117 (1.13%)
Orthostatic Hypotension	107 (1.04%)
Fall	106 (1.03%)
Blood Pressure Increased	98 (.95%)
	Show More
Fatigue	96 (.93%)
Asthenia	91 (.88%)
Renal Failure Acute	86 (.83%)
Nausea	85 (.82%)
Headache	75 (.73%)
Blood Pressure Decreased	74 (.72%)
Malaise	72 (.7%)
Completed Suicide	69 (.67%)
Hypoglycaemia	65 (.63%)
Hypoxia	62 (.6%)
Vomiting	62 (.6%)
Blood Pressure Systolic Increased	61 (.59%)
Oedema Peripheral	61 (.59%)
Suicide Attempt	60 (.58%)
Bradycardia	59 (.57%)
Blood Creatinine Increased	58 (.56%)
Floppy Iris Syndrome	57 (.55%)
Atrial Fibrillation	56 (.54%)
Dehydration	54 (.52%)
Pneumonia	52 (.5%)
Condition Aggravated	51 (.49%)
Diarrhoea	50 (.48%)
Pancreatitis Acute	50 (.48%)
Metabolic Acidosis	48 (.47%)
Death	46 (.45%)
Overdose	45 (.44%)
Cardiac Failure	44 (.43%)
Vision Blurred	44 (.43%)
Palpitations	43 (.42%)
Renal Failure	43 (.42%)
Anxiety	42 (.41%)
Heart Rate Increased	41 (.4%)
Blood Pressure Inadequately Control...	39 (.38%)
Pyrexia	39 (.38%)
Thrombocytopenia	39 (.38%)
Abdominal Pain Upper	38 (.37%)
Cough	38 (.37%)
Chest Pain	37 (.36%)
Myalgia	37 (.36%)
Renal Impairment	37 (.36%)
Shock	37 (.36%)
Somnolence	37 (.36%)
Cardiac Arrest	36 (.35%)
Gait Disturbance	34 (.33%)
Pleural Effusion	34 (.33%)
Cerebrovascular Accident	33 (.32%)
Myocardial Infarction	33 (.32%)
Tremor	33 (.32%)
Dysuria	32 (.31%)
Oedema	32 (.31%)
Pain	32 (.31%)
Presyncope	32 (.31%)
Weight Decreased	32 (.31%)
Arthralgia	31 (.3%)
Blood Urea Increased	31 (.3%)
Pain In Extremity	31 (.3%)
Pulmonary Oedema	31 (.3%)
C-reactive Protein Increased	30 (.29%)
Rhabdomyolysis	30 (.29%)
Abdominal Pain	29 (.28%)
Aspartate Aminotransferase Increase...	29 (.28%)
Constipation	29 (.28%)
Depressed Level Of Consciousness	29 (.28%)
Epistaxis	29 (.28%)
Platelet Count Decreased	29 (.28%)
Drug Effect Decreased	28 (.27%)
Feeling Abnormal	28 (.27%)
Prostate Cancer	28 (.27%)
Anaemia	27 (.26%)
Crystalluria	27 (.26%)
Tachycardia	27 (.26%)
Alanine Aminotransferase Increased	26 (.25%)
Blood Glucose Increased	26 (.25%)
Multiple Drug Overdose Intentional	26 (.25%)
Sinus Bradycardia	26 (.25%)
Cerebral Infarction	25 (.24%)
Dialysis	25 (.24%)
Haemodialysis	25 (.24%)
Hyperkalaemia	25 (.24%)
Lethargy	25 (.24%)
Lactic Acidosis	24 (.23%)
Nocturia	24 (.23%)
Paraesthesia	24 (.23%)
Pollakiuria	24 (.23%)
Rash	24 (.23%)
Urinary Retention	24 (.23%)
Cataract	23 (.22%)
Drug Hypersensitivity	23 (.22%)
Drug Toxicity	23 (.22%)
Multiple Drug Overdose	23 (.22%)

Share/Embed Graph Export Data

This graph shows the top adverse events submitted to the FDA for Doxazosin, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Doxazosin is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Adverse Event Categories for Doxazosin

What are the most common Doxazosin adverse events reported to the FDA?

Neurological	789 (7.65%)
Decreased And Nonspecific Blood Pre...	481 (4.66%)
Therapeutic And Nontherapeutic Effe...	388 (3.76%)
Cardiac And Vascular Investigations	385 (3.73%)
Cardiac Arrhythmias	350 (3.39%)
Respiratory	343 (3.32%)
Gastrointestinal Signs	313 (3.03%)
Renal Disorders	258 (2.5%)
Infections - Pathogen Unspecified	231 (2.24%)
Urinary Tract Signs	225 (2.18%)
Epidermal And Dermal Conditions	203 (1.97%)
	Show More
Medication Errors	198 (1.92%)
Injuries	187 (1.81%)
Vascular Hypertensive	146 (1.41%)
Electrolyte And Fluid Balance Condi...	145 (1.41%)
Muscle	142 (1.38%)
Hematology Investigations	139 (1.35%)
Suicidal And Self-injurious Behavio...	139 (1.35%)
Renal And Urinary Tract Investigati...	129 (1.25%)
Hepatic And Hepatobiliary	125 (1.21%)
Procedural And Device Related Injur...	113 (1.09%)
Central Nervous System Vascular	110 (1.07%)
Musculoskeletal And Connective Tiss...	108 (1.05%)
Heart Failures	94 (.91%)
Vision	90 (.87%)
Gastrointestinal Motility And Defec...	89 (.86%)
Hepatobiliary	88 (.85%)
Cardiac Disorder Signs	87 (.84%)
Coronary Artery	87 (.84%)
Glucose Metabolism Disorders	87 (.84%)
Anxiety Disorders	82 (.79%)
Headaches	77 (.75%)
Metabolic, Nutritional And Blood Ga...	77 (.75%)
Physical Examination Topics	77 (.75%)
Acid-base	75 (.73%)
Joint	75 (.73%)
Movement Disorders	75 (.73%)
Lower Respiratory Tract Disorders	70 (.68%)
Anemias Nonhemolytic And Marrow Dep...	69 (.67%)
Upper Respiratory Tract Disorders	69 (.67%)
Exocrine Pancreas Conditions	58 (.56%)
Fatal Outcomes	57 (.55%)
Hematological And Lymphoid Tissue T...	54 (.52%)
Bone And Joint Injuries	52 (.5%)
Allergic Conditions	51 (.49%)
Bronchial Disorders	51 (.49%)
Arteriosclerosis, Stenosis, Vascula...	49 (.47%)
Lifestyle Issues	49 (.47%)
Sleep Disorders	49 (.47%)
Body Temperature Conditions	48 (.47%)
Mental Impairment	48 (.47%)
Water, Electrolyte And Mineral	48 (.47%)
White Blood Cell	48 (.47%)
Chemical Injury And Poisoning	47 (.46%)
Enzyme	46 (.45%)
Skin Appendage Conditions	46 (.45%)
Platelet	44 (.43%)
Anterior Eye Structural Change, Dep...	40 (.39%)
Cardiac Valve	40 (.39%)
Product Quality Issues	40 (.39%)
Prostatic Disorders	39 (.38%)
Sexual Function And Fertility	39 (.38%)
Reproductive Organ And Breast Inves...	37 (.36%)
Myocardial	35 (.34%)
Reproductive Neoplasms Male Maligna...	35 (.34%)
Gastrointestinal Hemorrhages	34 (.33%)
Pleural	34 (.33%)
Nephropathies	33 (.32%)
Penile And Scrotal Disorders	33 (.32%)
Depressed Mood Disorders	32 (.31%)
Seizures	32 (.31%)
Protein And Chemistry Analyses	31 (.3%)
Inner Ear And Viiith Cranial Nerve	30 (.29%)
Appetite And General Nutritional	29 (.28%)
Gastrointestinal Ulceration And Per...	29 (.28%)
Viral Infectious	29 (.28%)
Deliria	28 (.27%)
Vascular	28 (.27%)
Gallbladder	27 (.26%)
Male Genital Tract Therapeutic Proc...	27 (.26%)
Ocular Neuromuscular	24 (.23%)
Angiedema And Urticaria	22 (.21%)
Coagulopathies And Bleeding Diathes...	22 (.21%)
Disturbances In Thinking	22 (.21%)
Therapeutic Procedures And Supporti...	22 (.21%)
Bacterial Infectious	21 (.2%)
Gastrointestinal Conditions	21 (.2%)
Ocular Infections, Irritations And ...	21 (.2%)
Salivary Gland Conditions	21 (.2%)
Hearing	20 (.19%)
Skin Vascular Abnormalities	20 (.19%)
Eye	19 (.18%)
Gastrointestinal Therapeutic Proced...	19 (.18%)
Immunology And Allergy	19 (.18%)
Lipid Analyses	19 (.18%)
Oral Soft Tissue Conditions	19 (.18%)
Psychiatric	19 (.18%)
Tongue Conditions	19 (.18%)
Gastrointestinal Neoplasms Malignan...	17 (.16%)
Peritoneal And Retroperitoneal Cond...	17 (.16%)
Toxicology And Therapeutic Drug Mon...	17 (.16%)

Share/Embed Graph Export Data

This graph shows the top categories of adverse events submitted to the FDA for Doxazosin, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Doxazosin is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.